In HFrEF patients, reduced doses of sacubitril / valsartan do not result in increased mortality or heart failure hospitalizations compared to target dose. A retrospective cohort study
26 May 2018 (00:00 - 00:00)
Organised by:
About the speaker
Hospital San Gennaro - ASL Napoli 1 Centre, Naples (Italy)
38 More presentations in this session
Miss M. Vester (Leiden, NL)
Associate Professor O. Havakuk (Tel Aviv, IL)
Professor Z. RAISSUNI (Tanger, MA)
Access the full session
The Event
Heart Failure 2018
26 May - 29 May 2018
You may be interested in
Congress Presentation
Congress Presentation
